Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

OXF BD 02 is an inhibitor of bromodomain 1 (BD1) in bromodomain-containing protein 4 (BRD4; IC50 = 382 nM).1 It is selective for BRD4 BD1 over a panel of 60 bromodomain-containing proteins but does inhibit CREB-binding protein (CBP) at 25 µM. OXF BD 02 is cytotoxic to MV4-11 acute myeloid leukemia (AML) cells (IC50 = 0.794 nM) but not A549 or H1975 lung cancer cells (IC50s = >10 µM for both) or U2OS osteosarcoma or HeLa cervical cancer cells (IC50s = >100 µM for both). OXF BD 02 also binds to recombinant S. mansoni BRD3 (SmBRD3) that contains BD1 and BD2 (Kd = 683 nM) but not recombinant BD2 of SmBRD3.2
WARNING This product is not for human or veterinary use.
1. Optimization of 3,5-
2. Small molecule ligands of the BET-